| Trial ID: | L5584 |
| Source ID: | NCT00423215
|
| Associated Drug: |
Insulin Glargine (Lantus)
|
| Title: |
LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Insulin glargine (LANTUS)
|
| Outcome Measures: |
Primary: Measure of Glycolysated Haemoglobin (HbA1c) level reduction, Delta between the treatment start and the end of the study (i.e. 4 months +/- 2 weeks) | Secondary: Measure of Fasting Blood Glucose (FBG) level reduction, Delta between the treatment start and the end of the study (i.e. 4 months +/- 2 weeks)|Investigator assessment, At the end of the study (i.e. 4 months +/- 2 weeks)|Insulin dose, At the end of the study (i.e. 4 months +/- 2 weeks)|Patient's satisfaction, At the end of the study (i.e. 4 months +/- 2 weeks)
|
| Sponsor/Collaborators: |
Sponsor: Sanofi
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
1007
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2006-03
|
| Completion Date: |
2008-05
|
| Results First Posted: |
|
| Last Update Posted: |
2009-06-15
|
| Locations: |
Sanofi-Aventis Administrative Office, Natanya, Israel
|
| URL: |
https://clinicaltrials.gov/show/NCT00423215
|
